MedTrace Logo

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

NCT05180799 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2025-06-15

No results posted yet for this study

Summary

The objective of this study is to assess safety and efficacy of BA3071 in solid tumors

Conditions

Interventions

BIOLOGICAL

BA3071

Conditionally active biologic (CAB) antibody that binds to CTLA-4

BIOLOGICAL

Nivolumab

Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1

BIOLOGICAL

Pembrolizumab

Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor

DRUG

Pemetrexed (Alimta)

pemetrexed with either cisplatin or carboplatin

Sponsors & Collaborators

  • BioAtla, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-03
Primary Completion
2025-03-19
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05180799 on ClinicalTrials.gov